Moore Capital Management LP purchased a new stake in Pharvaris N.V. (NASDAQ:PHVS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 44,001 shares of the company's stock, valued at approximately $1,522,000. Moore Capital Management LP owned about 0.07% of Pharvaris as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also modified their holdings of PHVS. Seven Fleet Capital Management LP grew its position in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company's stock valued at $8,947,000 after acquiring an additional 261,355 shares during the last quarter. PSP Research LLC bought a new position in shares of Pharvaris in the fourth quarter worth about $569,000. DV Trading LLC acquired a new stake in shares of Pharvaris in the 1st quarter valued at approximately $4,067,000. venBio Partners LLC acquired a new stake in shares of Pharvaris in the 2nd quarter valued at approximately $160,569,809. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Pharvaris during the 2nd quarter valued at approximately $3,649,000.
Pharvaris Price Performance
Shares of Pharvaris stock opened at $34.61 on Tuesday. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -11.35 and a beta of -2.31. Pharvaris N.V. has a one year low of $20.65 and a one year high of $38.13. The stock's 50-day moving average is $34.64 and its 200 day moving average is $30.82.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). On average, sell-side analysts expect that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the sale, the insider owned 46,275 shares in the company, valued at approximately $1,428,509.25. This trade represents a 5.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anne Lesage sold 30,703 shares of the business's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the transaction, the insider directly owned 93,969 shares of the company's stock, valued at approximately $3,334,959.81. This represents a 24.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 121,325 shares of company stock worth $4,270,425.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price objective on Pharvaris from $51.00 to $52.00 and gave the stock an "outperform" rating in a research report on Thursday, August 13th. Wells Fargo & Company began coverage on Pharvaris in a research report on Wednesday, July 15th. They issued an "overweight" rating and a $55.00 target price for the company. HC Wainwright restated a "buy" rating on shares of Pharvaris in a report on Friday, August 14th. Finally, UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of "Moderate Buy" and an average target price of $51.08.
View Our Latest Report on PHVS
Pharvaris Company Profile
(
Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
